Therefore, this study and our study showed that KLF4 represses DYRK2 gene expression in CML, while in breast cancer, DYRK2 prevents androgen receptor-mediated activation of the KLF4 gene. This evidence concerns the gene DYRK2 and chronic myelogenous leukemia, BCR-ABL1 positive.